For the Athlete Who Has It All
In an age of ultramarathons, Ironman triathlons and crowds chugging up Mount Everest, long-distance butterfly swimming is becoming a new and less-crowded frontier for fitness fanatics. online.wsj.com |
Seattle Genetics, Inc. Q2 2010 Earnings Call Transcript
Seattle Genetics, Inc. (SGEN)Q2 2010 Earnings CallJuly 27, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Biotech's Slow Week Gets Stirred by a Few Smaller Deals
The Burrill Report submits: By Marie DaghlianThe acquisition of two small companies highlighted a quiet deal making week in the life sciences. Endo Pharmaceuticals (ENDP) agreed to acquire its partner Penwest Pharmaceuticals (PPCO) in a deal that looks promising for both companies. For Endo, the transaction provides access to Penwest’s royalty interest in pain drug Opana ER, a Penwest’s experimental pipeline, and its new delivery technology. Complete Story » seekingalpha.com |
Immunogen, Exelixis: Right Deals at the Right Time
Ohad Hammer submits:Yesterday, both Immunogen (IMGN) and Exelixis (EXEL) announced two important partnership deals. As with any deal, both companies enjoy an injection of non-dilutive funds as well as a vote of confidence for the companies’ technologies. This time, however, it seems the deals, which could not have come in a better time, represent much more than that. Immunogen announced a broad licensing deal with Novartis (NVS) which provides the pharma giant with rights to use Immunogen’s antibody drug conjugate (ADC) technology for an undisclosed number of targets. The numbers demonstrate the huge appreciation in the value of Immunogen’s technology compared to several years ago. The deal includes an upfront payment of $45M as well as $200M in milestone payments for every program Novartis chooses to develop. For the sake of comparison, current agreements with Genentech and Sanofi Aventis (SNY) entail milestone payments of in the $20-40 million range.Complete Story » seekingalpha.com |
Panel Widens Probe of Bare-Bones Health Plans
A congressional committee is widening its investigation of bare-bones health-insurance policies to encompass potentially hundreds of plans offered by low-wage employers. online.wsj.com |